Capital Analysts LLC Sells 74,866 Shares of CVS Health Co. (NYSE:CVS)

Capital Analysts LLC decreased its position in CVS Health Co. (NYSE:CVS) by 95.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,862 shares of the pharmacy operator’s stock after selling 74,866 shares during the quarter. Capital Analysts LLC’s holdings in CVS Health were worth $173,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of CVS. Ridgewood Investments LLC raised its stake in shares of CVS Health by 255.7% in the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 450 shares during the period. Stonebridge Financial Group LLC bought a new position in shares of CVS Health in the fourth quarter worth about $28,000. Hopwood Financial Services Inc. bought a new position in shares of CVS Health in the fourth quarter worth about $29,000. Financial Perspectives Inc raised its stake in shares of CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator’s stock worth $36,000 after buying an additional 466 shares during the period. Finally, MidAtlantic Capital Management Inc. raised its stake in shares of CVS Health by 112.1% in the fourth quarter. MidAtlantic Capital Management Inc. now owns 827 shares of the pharmacy operator’s stock worth $37,000 after buying an additional 437 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 0.6 %

CVS stock opened at $64.91 on Tuesday. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $71.45. The stock has a market capitalization of $81.84 billion, a price-to-earnings ratio of 17.74, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The firm’s fifty day simple moving average is $66.45 and its two-hundred day simple moving average is $58.75.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 4.10%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s dividend payout ratio is presently 72.68%.

Insider Buying and Selling

In related news, SVP James David Clark sold 7,513 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael F. Mahoney purchased 30,000 shares of CVS Health stock in a transaction that occurred on Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

CVS has been the topic of several recent research reports. Wells Fargo & Company raised their price objective on CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Argus set a $77.00 price objective on CVS Health in a research note on Tuesday, February 18th. Wolfe Research lifted their target price on CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Barclays lifted their target price on CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, UBS Group decreased their target price on CVS Health from $62.00 to $59.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $71.83.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.